May 17, 2026 · Hospital Consolidation · Ways & Means · NBER

Share

Hospitals Promised Cheaper Care After Merging. Prices Are Up 300%.

On February 10, 2026, Senators Elizabeth Warren (D-MA) and Josh Hawley (R-MO) — a pairing that does not happen by accident — introduced the Break Up Big Medicine Act (S. 3822). Eleven weeks later, on April 28, 2026, House Ways and Means Chairman Rep. Jason Smith (R-MO) told a row of hospital-system CEOs to their faces that the prices their hospitals charge are “borderline extortion.”

The numbers behind the bipartisan fury are stark. Hospital prices in the United States have risen roughly 300% in two decades — faster than any other sector. Between 2000 and 2020, the Federal Trade Commission challenged exactly 13 of 1,164hospital mergers, per NBER Working Paper 32613. About 1.1%. Today, 90% of U.S. metro areas have hospital markets the federal government classifies as “highly concentrated.”

The merger pitch is always the same — scale, efficiency, lower cost, better care. The peer-reviewed record on every one of those claims is that they did not happen. Quality measurably worsened in 77% of studied post-merger systems. Private-equity hospital acquisitions raised hospital-acquired adverse events by 25%. And 193 rural hospitals have closed since 2005, with 62 of those closures coming in 2017-2024 alone.

• 300%growth in U.S. hospital prices over two decades — the fastest of any sector (House Ways and Means)
• 13 / 1,164FTC merger challenges, 2000-2020 — roughly 1% (NBER Working Paper 32613)
• 47%of U.S. physicians system-employed in 2024, up from under 30% in 2012 (GAO-25-107450)
• 90%of U.S. metro areas have hospital markets the federal government classifies as highly concentrated (HHS RFI Response)
• +25%rise in hospital-acquired adverse events after private-equity hospital acquisitions (JAMA · summarized in Harvard Gazette)
• 193rural hospitals closed since 2005, including 62 in 2017-2024 (Penn LDI · ACS)
• $80,000,000,000projected consumer savings from RFK Jr.'s CMS price-transparency rule effective April 1, 2026 (HHS)
• S. 3822the Break Up Big Medicine Act — Warren (D-MA) + Hawley (R-MO), Feb 10, 2026

For a quarter century, healthcare consolidation has been one of those Washington problems that everyone described as bipartisan and nobody actually fought on a bipartisan basis. On February 10, 2026, that changed. Sen. Elizabeth Warren (D-MA) and Sen. Josh Hawley (R-MO) introduced the Break Up Big Medicine Act — S. 3822— barring vertical integration between large hospital systems, insurers, and physician practices, and giving regulators sharper teeth on existing rollups.

“There's no question that massive health care companies have created layers of complexity to jack up the price of everything from prescription drugs to a visit to the doctor.”

Sen. Elizabeth Warren (D-MA) · Feb 10, 2026 · press release accompanying S. 3822

“Americans are paying more and more for healthcare while the quality of care gets worse and worse.”

Sen. Josh Hawley (R-MO) · Feb 10, 2026 · press release accompanying S. 3822

Eleven weeks later, the House version of the same political moment arrived. On April 28, 2026, Ways and Means Chairman Rep. Jason Smith (R-MO) opened a hearing with a row of hospital-system CEOs sitting across from him and told them, on the record, what the published evidence shows.

“The prices you charge patients are borderline extortion. Hospital consolidation and mergers, that lead to ever-growing market power, are fueling the borderline extortionary prices hospitals charge patients.”

Rep. Jason Smith (R-MO) · House Ways and Means · April 28, 2026

Smith later sharpened the point on CNBC: tax-exempt “not-for-profit” hospital systems, he said, “look like hedge funds with hospital beds.”

NBER Working Paper 32613 — the Yale Tobin Center hospital-mergers study by Brot-Goldberg, Cooper, Craig, and Klarnet — quantified the federal enforcement gap in one number. Between 2000 and 2020, the FTC challenged 13 of 1,164 hospital mergers. About 1.1%. Mergers in already-concentrated markets raised commercial prices anywhere from 6% to 65%, depending on overlap and market structure. The authors estimated that 53 mergers per year between 2010 and 2015 generated roughly $204,000,000per year in additional private-insured spending — a recurring tax on commercial health plans paid out of premiums and paychecks.

The Government Accountability Office worked the same problem from the Medicare side. GAO-25-107450 found that hospital acquisitions of independent primary-care practices from 2013 to 2016 raised Medicare imaging costs by $40,000,000 and Medicare lab-test costs by $33,000,000 — for the exact same service. Once a gastroenterologist was acquired by a hospital, the average colonoscopy cost Medicare an additional $3,851 per consolidated provider per year.

“Hospital mergers don't make care better — they just make it pricier.”

Penn LDI Fellows · 2024 research summary

The trend is one direction. 47% of U.S. physicians were system-employed in 2024— up from under 30% in 2012, per GAO-25-107450. About one-third of all U.S. doctors now work for a hospital or hospital-owned group. The independent practice, once the default unit of American medicine, is now a minority configuration.

Once a physician practice is acquired, two things happen on the bill. First, Medicare and many commercial plans pay a hospital-based “facility fee” on top of the professional fee for the same office visit. Second, contracting leverage flips: the hospital system negotiates rates for the practice using the system’s aggregate market power. The empirical literature is consistent — not a single major peer-reviewed study has shown a sustained price decrease following a hospital-physician acquisition in a concentrated market.

The market structure on the hospital side of that bargaining table is the other half of the story. The HHS Consolidation in Health Care Markets RFI Response Report (Jan 15, 2025) found 90% of U.S. metro areashave hospital markets classified as “highly concentrated” on the Herfindahl-Hirschman Index. That is the federal government’s own definition of the antitrust danger zone.

If consolidation actually delivered the promised efficiency and quality gains, the price premium might be defensible. It does not. The American College of Surgeons published a synthesis in its journal in 2024 concluding flatly that “improved health care value cannot be achieved by hospital mergers and acquisitions alone.” A 2024 systematic review surveyed by Penn LDI fellows found that 77% of post-merger quality studies showed measurably worse quality or no improvement.

Private-equity acquisitions of hospitals have produced the most damning evidence. A 2024 JAMA study covered by the Harvard Gazette found that hospitals acquired by private equity saw a 25% rise in hospital-acquired adverse events— bloodstream infections, falls, central-line complications — relative to matched control hospitals. In January 2025, the FTC settled an antitrust case against a private equity firm that had rolled up anesthesia practices (the USAP matter), the first such PE-rollup challenge brought through to settlement.

“Improved health care value cannot be achieved by hospital mergers and acquisitions alone.”

Journal of the American College of Surgeons · 2024

On April 1, 2026, the CMS hospital price-transparency rule pushed by HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz took effect. Hospitals must now post machine-readable files of actual negotiated rates — not chargemaster fantasy — for the 300 most common shoppable services. HHS’s own analysis projected $80,000,000,000 in consumer savings as patients and self-insured plans shop on real prices for the first time.

Transparency is the demand-side reform. The supply-side reform sits in S. 3822, the Warren-Hawley Break Up Big Medicine Act. The bill bars new vertical mergers between large hospital systems, insurers, and physician practices; gives DOJ and the FTC stronger pre-merger review of healthcare deals above defined size thresholds; and creates structural-separation remedies for the largest integrated systems. The bill had not been voted out of committee at the time of publication, but Warren-Hawley as a Senate floor pairing on a single healthcare bill is itself the news.

The Trump administration’s posture on hospital pricing has tracked closely with the transparency-and-accountability frame — consistent with what then-candidate Trump described as a “Great Healthcare Plan” that would force insurers and hospitals to post real prices.

With the FTC challenging only 13 of 1,164 mergers from 2000 to 2020, the largest hospital-antitrust recoveries of the past decade came from state attorneys general, not the federal government. Xavier Becerra (D), as California Attorney General, secured a $575,000,000 settlement with Sutter Health over anticompetitive contracting and tying practices — one of the largest hospital antitrust recoveries in U.S. history. His successor, Rob Bonta (D-CA), secured a $430,000,000 settlement covering the UC/UCSF-Dignity Health affiliation.

On the federal side, the FTC under Chair Lina Khan brought one of the highest-profile recent hospital-merger challenges — FTC v. Novant Health in January 2024 — to block Novant’s $320,000,000acquisition of two Community Health Systems hospitals in North Carolina. The deal was ultimately abandoned. In January 2025, the FTC settled an antitrust case against a private-equity firm over a roll-up of U.S. Anesthesia Partners (USAP) practices in Texas — the first private-equity rollup settled through to a remedy.

Three facts — lifted from the federal record, not from cable news — sit at the center of this story. Hospital prices have risen roughly 300% over two decades, the FTC challenged 13 of 1,164 mergers, and the post-merger evidence on quality and cost is, in 77% of studies, either no better or measurably worse. The lobbying argument that scale would lower prices was sold to Congress, antitrust regulators, and the public for a generation. The peer-reviewed record — NBER, Yale, GAO, Penn LDI, ACS, JAMA — says that argument did not hold.

That is also why Warren-Hawley is a real Senate pairing in 2026 and not a press-release stunt. The frame that hospital pricing is “borderline extortion” came from a House Republican chairman, not a left-wing think tank. The 300% number is the chairman’s own committee’s number. The 13-of-1,164 number is the federal government’s own number. The 193 closed rural hospitals are real towns. There is a bipartisan Senate bill, a Trump-administration price-transparency rule, and state attorneys general from both parties writing the kind of settlements the FTC mostly did not. The accountability gap is not subtle and it is not contested in the published evidence.